In conclusion, considering anti-RANKL and anti-osteoclast therapies have shown to be beneficial for bone loss in arthritis patients in clinical trial [34], these results provided a new insight that sinomenine might be useful for the treatment of RA patients partly via attenuating osteoclast formation and RANKL related signaling pathways. The gene discussed is TNFSF11; the disease is rheumatoid arthritis.